Commentary by a child psychiatrist in industry on the assessment of drug safety

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 3, 2007, Pages 288-291

  Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD PSYCHIATRY; CLINICAL STUDY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; NOTE; POSTMARKETING SURVEILLANCE; PSYCHIATRIST; RISK BENEFIT ANALYSIS;

CHILD; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34447521879     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0031     Document Type: Note

References (4)

1. Ahmad SR, Goetsch RA, Marks NS: Spontaneous Reporting Systems. In BL Strom (ed.). Pharmacoepidemiology, 4th ed. London (England): Wiley & Sons, 2005.
2. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM: An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: Comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 64:898-906, 2003.
3. JT Chang Chang JT, Staffa JA, Parks M, Green L: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Safety 13:417-426, 2004.
4. Zarin DA, Tse T, Ide NC: Trial registration at Clinical-Trials.gov between May and October 2005. N Engl J Med 353:2779-2787, 2005.